Atlas Trials

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Clinical trial NCT04783935 · COMPLETED

Trial details

NCT number
NCT04783935
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2021-03-10
Primary completion
2023-09-21
Enrollment
219

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.